A Phase I Clinical Study of YN003 in the Treatment of Glioma

Inclusion Criteria:

* Voluntarily sign the informed consent form, understand the study, and be willing to comply with the protocol and complete all study procedures.
* Male or female subjects 18 years ≤ aged ≤ 70 years.
* Histologically confirmed recurrent or progressive glioma, including glioblastoma, as defined by the 2021 WHO Classification of Tumors of the Central Nervous System, Grade 3 to Grade 4, following standard therapy.Excluding re-irradiation for same lesions
* Karnofsky Performance Status (KPS) ≥60.
* At least one measurable lesion per RANO 2.0 criteria.
* Have adequate hematologic, cardiac, hepatic, renal, coagulation, and pulmonary function at final screening.
* Have completed the required washout period for prior therapies before dosing on Day 1.
* Corticosteroid dose must be stable or tapering within 7 days prior to dosing.

Exclusion Criteria:

* Participation in another interventional clinical study within 1 month prior to the date when subject signed the consent form.
* Receipt of a live vaccine within 30 days prior to study treatment.
* Pregnant or breastfeeding women.
* Clinically significant intracranial hypertension (e.g., impending brain herniation or requiring urgent palliative intervention) or uncontrolled seizures. Subjects requiring antiepileptic drugs are eligible only if the dose has been stable for ≥ 14 days prior to first dosing
* Toxicities from prior anticancer therapy that have not recovered to CTCAE v6.0 Grade ≤1, except for alopecia or other events considered tolerable by the investigator.
* Contraindications to MRI, including but not limited to pacemakers, epicardial pacing leads, infusion pumps, aneurysm clips, metal fragments, metallic prostheses, magnetic implants, intraocular metal objects, or non-removable metallic dental implants.
* Uncontrolled or severe cardiovascular or cerebrovascular disease